DCRI Shares Research, Insights, and Expertise during 2024 AHA Scientific Sessions
Faculty experts from the Duke Clinical Research Institute shared new research results, provided thought-provoking insights, and championed therapeutic guidelines and best practices as part of more than 40 sessions during the 2024 American Heart Association (AHA) Scientific Sessions.
DCRI’s Schanberg Receives American College of Rheumatology Master Designation
Duke Clinical Research Institute (DCRI) faculty member Laura Schanberg, MD, was rece
DCRI-Led Research Consortium Aims to Reduce Kidney Disease Disparities Tied to Structural Racism
Some 37 million people in the U.S. – more than one in seven adults – have chronic kidney disease (CKD). But not everyone faces the same risk.
Hernandez Honored with QCOR Outstanding Lifetime Achievement Award
The American Heart Association's (AHA) Council on Quality of Care and Outcomes Research (QCOR) Council bestowed the Outstanding Lifetime Achievement Award on Adrian Hernandez, MD, MHS, the executive director of the Duke Clinical Research Institute (DCRI) and vice dean at the Duke University School of Medicine, during the AHA Scientific Sessions on November 16. The award is presented annually at the AHA Scientific Sessions to a QCOR Council member for their significant long-term contributions to outcomes research and the improvement of cardiovascular care.
All in the Family
Sisters Rebecca Kirkland and Mary Trent Jones are no strangers to volunteering, spending decades serving on boards, with Rebecca on the Duke University Board of Trustees and the D
DCRI Celebrates 10 Years of Supporting Patient-Centered Research Powered by PCORnet®
2024 marks the 10-year anniversary of PCORnet® — a national patient-centered clinical research network developed with funding from the Patient Centered Outcomes Research Institute (PCORI) to suppor
DCRI Shares Late-Breaking Results, Expert Insights at ESC Congress
Faculty members and fellows of the Duke Clinical Research Institute (DCRI) shared their expertise during the European Society of Cardiology Congress (ESC) in London, Aug. 30-Sept. 2. Late-breaking trial results presented by DCRI faculty at the meeting offered new insights into drug and device efficacy and capabilities.
First Parkinson’s Disease Patient Treated with ALX-001 in Allyx Therapeutics, DCRI Study
Allyx Therapeutics has announced that the first patient has been dosed with its lead compound, ALX-001, in a new clinical study assessing safety, pharmacokinetics and potential therapeutic response in patients with Parkinson’s disease. ALX-001 is a highly selective, first-in-class, synapse-targeted, disease-modifying oral therapy. Allyx Therapeutics is a clinical-stage biotechnology company working to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases.